Carson Wealth (CWM LLC)
SPRY icon

Carson Wealth (CWM LLC)’s ARS Pharmaceuticals SPRY Stock Holding History

Carson Wealth (CWM LLC)’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.7K Buy
834
+772
+1,245% +$7.4K ﹤0.01% 4935
2025
Q4 		$1K Sell
62
-2,485
-98% -$24.2K ﹤0.01% 5280
2025
Q3 		$26K Buy
2,547
+1,806
+244% +$25.9K ﹤0.01% 3971
2025
Q2 		$13K Buy
741
+114
+18% +$1.65K ﹤0.01% 4178
2025
Q1 		$8K Buy
627
+562
+865% +$6.76K ﹤0.01% 4239
2024
Q4 		$1K Sell
65
-1
-2% -$14 ﹤0.01% 4806
2024
Q3 		$1K Buy
66
+29
+78% +$345 ﹤0.01% 4711
2024
Q2 		$0 Buy
+37
New +$328 ﹤0.01% 4917
2023
Q4 		– Sell
-18
Closed – – 4494
2023
Q3 		$0 Buy
+18
New +$118 ﹤0.01% 4510

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Carson Wealth (CWM LLC)'s SPRY Position: Q1 2026 in Review

Carson Wealth (CWM LLC) increased its ARS Pharmaceuticals (SPRY) stake by 1,245% in Q1 2026, buying an estimated $7.4K and bringing the position to 834 shares worth $6.7K. The position accounts for ﹤0.01% of the portfolio, ranked #4935.

Carson Wealth (CWM LLC) first reported a position in SPRY in Q3 2023 and has held it in 9 quarters since. The position peaked at $26K in Q3 2025. 203 funds tracked by Wall St. Rank hold SPRY as of Q1 2026.

  • Carson Wealth (CWM LLC) held 834 shares of ARS Pharmaceuticals worth $6.7K as of Q1 2026.
  • Carson Wealth (CWM LLC) bought 772 ARS Pharmaceuticals shares in Q1 2026, an estimated $7.4K.
  • ARS Pharmaceuticals made up ﹤0.01% of Carson Wealth (CWM LLC)'s portfolio in Q1 2026, its #4935 holding.
  • Carson Wealth (CWM LLC) first reported a position in ARS Pharmaceuticals in Q3 2023 and has held it in 9 quarters since.
  • Carson Wealth (CWM LLC)'s ARS Pharmaceuticals position peaked at $26K in Q3 2025.
  • 203 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2026.

Based on Carson Wealth (CWM LLC)'s 13F filing for Q1 2026, filed 14 May 2026.